MiniMed <sup>TM</sup> 780G Hybrid Closed-Loop Systems Improves Markers of Vascular and Endothelial Function in Patients with Type 1 Diabetes: Association with Continuous Glucose Monitoring Metrics
MiniMed<sup>TM</sup> 780G HCLS demonstrated superiority over MDI or SGLT-2i in terms of glycemic control and cardiovascular function in T1D. These results support HCLS as a preferred therapeutic option for the prevention of cardiometabolic disease in individuals with T1D, in a population whose cardiovascular burden is often underrecognized in both research and clinical practice.
Authors
- Loukia Pliouta (ORCID: https://orcid.org/0009-0007-8693-4443)
- J Thymis (ORCID: https://orcid.org/0000-0002-3916-5350)
- George Pavlidis (ORCID: https://orcid.org/0000-0003-3220-3446)
- Lambadiari
- G. Dimitriadis
- Κ Katogiannis (ORCID: https://orcid.org/0000-0003-1631-5210)
- Aikaterini Kountouri (ORCID: https://orcid.org/0000-0001-5829-7327)
- Emmanouil Korakas (ORCID: https://orcid.org/0000-0002-7813-5488)
- Goran Petrovski (ORCID: https://orcid.org/0000-0002-8622-2186)
- S Liatis
- V. Agapitou
- I Ikonomidis
Institutions
- National and Kapodistrian University of Athens (GR)
- Laiko General Hospital of Athens (GR)
- Sidra Medical and Research Center (QA)
- University General Hospital Attikon (GR)
Publication Details
- Journal
- Diabetes Technology & Therapeutics
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1177/15209156261417289
- Primary Topic
- Cardiovascular Health and Disease Prevention
- Type
- article
- Field-Weighted Citation Impact
- 0.00